# TG THERAPEUTICS, INC. (TGTX) FY2026 Q2 P&L / Income Statement

- Company: TG THERAPEUTICS, INC. (TGTX)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001437749-26-025955
- Page: https://plicit.ai/financials/tgtx/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/tgtx-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 240,335,000 US dollars
- **Cost of revenue**: 41,194,000 US dollars
- **Gross profit (calculated)**: 199,141,000 US dollars
- **Operating expenses (calculated)**: 177,467,000 US dollars
- **Operating income**: 21,674,000 US dollars
- **Total other expense**: negative 11,440,000 US dollars
- **Net income before taxes**: 10,234,000 US dollars
- **Income tax expense**: 2,453,000 US dollars
- **Net income**: 7,781,000 US dollars
- **Product**: 235,794,000 US dollars
- **License Revenue**: 4,541,000 US dollars
- **Other research and development**: 87,267,000 US dollars
- **Stock-based compensation**: 8,070,000 US dollars
- **Other selling, general and administrative**: 62,325,000 US dollars
- **Stock-based compensation**: 19,805,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.